The Cancer Prevention Research Institute of Texas (CPRIT) has been active in granting new funding to researchers, academic institutions, and biotech businesses alike since the start of the new year. Now, the organization has just released a new round of RFAs that span a broad spectrum of new funding opportunities for virtually every facet of cancer research, development, and prevention efforts.
According to a CPRIT news release, the organization has released 11 new RFAs that specifically target cancer prevention, product development, and research. The Prevention category includes two RFAs, one for Competitive Continuation/Expansion projects, which allows prevention organizations already receiving CPRIT funding to continue their funding channel, and an Evidence-based Cancer Prevention services RFA, which seeks to fuel innovation and advancement in “the delivery of evidence-based cancer prevention and control clinical services and that propose to serve areas of the state not well addressed by current CPRIT funded projects.” In this way, these two RFAs for prevention cover a lot of ground in continuing valuable cancer prevention efforts, as well as developing new ones.
In the Product Development category, CPRIT appears to be aggressively targeting leading cancer biotech organizations, seeking to encourage them to relocate to the Lone Star State, while also looking to bolster continued commercialization by established Texas biotech firms. The Established Company Awards, for example, is seeking companies that already have at least one round of professional institutional investment under their belts, and must be headquartered in Texas. The New Company Awards RFA “seeks to support early stage “start-up” companies in the research and development of new products for the diagnosis, treatment, or prevention of cancer,” and while companies “must have a significant presence in Texas,” they need not currently be Texas-based, but simply willing to relocate. In addition, the Product Development category also includes Company Relocation Awards, which seek to attract companies who have previous received institutional funding and who are considering relocation to Texas, which would in turn help “establish infrastructure that is critical to the development of a robust industry, or fill a treatment or research gap” for cancer research and development.
Finally, the Research category of CPRIT’s new RFAs include three awards focused on individual investigators, and three others designed to recruit new research talent into the state. Among the new individual investigator opportunities is the highly anticipated Individual Investigator Research Awards For Cancer In children and Adolescents, the result of an impassioned effort on the part of Annette Leslie and the Carson Leslie Foundation.
Considering that the year is not even half over, there is still much more to be done at CPRIT to advance cancer research in the state of Texas. However, these new RFAs are bound to lead to a host of new projects that will make headlines in the months to come.